Summary by Futu AI
Altimmune announced completion of enrollment in Phase 2b IMPACT trial for pemvidutide in MASH, with top-line efficacy data expected in Q2 2025. The company successfully concluded its End-of-Phase 2 FDA meeting for the obesity program, gaining agreement on four pivotal Phase 3 trials design. Additionally, Altimmune plans to submit IND applications for pemvidutide in up to three new indications starting Q4 2024.Financial results for Q3 2024 showed cash, equivalents and short-term investments of $139.4M. Research and development expenses increased to $19.8M from $18.4M year-over-year, while G&A expenses rose to $5.0M from $4.5M. The company reported a net loss of $22.8M ($0.32 per share) compared to $20.7M ($0.39 per share) in Q3 2023.Recent clinical data presented at EASD demonstrated pemvidutide's compelling body composition benefits, including a lean loss ratio of 21.9% and 28.3% reduction in visceral adipose tissue at 2.4mg dose after 48 weeks. The company appointed Greg Weaver as CFO on November 11, 2024.
Comment(0)
Reason For Report